PRNewswire

Ahmedabad (Gujarat) [India]/ Atlanta [US], September 26: Senores Pharmaceuticals, Inc. announced the launch of Nicardipine Hydrochloride Capsules USP, 20 mg and 30 mg, a bioequivalent and therapeutically equivalent to Cardene Capsules, 20 mg and 30 mg, of Chiesi USA, Inc. in the U.S. market. The product will be marketed by Burel Pharmaceuticals, LLC.

Also Read | Bengaluru Bandh Update: Several Protesters Detained, Police High-Handedness Alleged.

Nicardipine Hydrochloride Capsules USP are indicated for the management of patients with chronic stable angina (effort-associated angina) and for the treatment of hypertension.

Senores Pharmaceuticals, Inc. has been granted a Competitive Generic Therapy (CGT) designation for Nicardipine Hydrochloride Capsules USP, 20 mg and 30 mg. Therefore, with this approval, Senores is eligible for 180 days of CGT exclusivity upon commercial marketing. 

Also Read | X New Feature Update: Elon Musk-Owned Platform To Roll Out Audio and Video Calls For Premium Users.

"We are pleased to announce the commercial launch of Nicardipine Hydrochloride Capsules in the U.S. through our marketing partner," stated Dhananjay Barot, Director, Senores Pharmaceuticals, Inc. "At Senores, the pursuit for better healthcare drives our actions. With this launch and an ever-expanding product portfolio, we envision a healthier tomorrow," stated Swapnil Shah, Managing Director, Senores Pharmaceuticals Limited.

About Senores Pharmaceuticals, Inc.  

Senores Pharmaceuticals, Inc., based in Georgia, USA is one of the fastest-growing pharmaceutical companies in the U.S. market. The company has more than 20 products commercially launched or filed with the USFDA.

For more information about Senores Pharmaceuticals, Inc., please visit  www.senorespharma.com

Senores Pharmaceuticals, Inc.

GeorgiaUSA

Photo: https://mma.prnewswire.com/media/2219865/Senores_Pharmaceticals.jpg

(ADVERTORIAL DISCLAIMER: The above press release has been provided by PRNewswire. ANI will not be responsible in any way for the content of the same)

(This is an unedited and auto-generated story from Syndicated News feed, LatestLY Staff may not have modified or edited the content body)